Neo­vacs signs €65M Chi­na deal; An­oth­er biotech CEO chat­ters on about a pos­si­ble buy­out

• Paris-based Neo­vacs says it signed up BioSense Glob­al for a €65 mil­lion deal cov­er­ing the de­vel­op­ment of its IFNα Ki­noid vac­cine to treat lu­pus and der­mato­myosi­tis in the Chi­nese mar­ket. BioSense CEO Andy Li says he will launch a Phase III in Chi­na for the drug, pro­vid­ed it clears an on­go­ing Phase IIb tri­al con­duct­ed by Neo­vacs. The cash cov­ers an up­front and mile­stones, though the an­nounce­ment didn’t break out the prices.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.